SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin informs about press release

23 Nov 2023 Evaluate

Lupin has informed that it enclosed a Press release regarding launch of the world’s first fixed-dose triple combination drug under the brand name Vilfuro-G® for the effective management of chronic obstructive pulmonary disease in India. 

The above information is a part of company’s filings submitted to BSE.


Lupin Share Price

2451.40 56.70 (2.37%)
29-Jul-2026 14:27 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1977.90
Dr. Reddys Labs. 1141.50
Cipla 1475.00
Lupin 2451.40
Zydus Lifesciences 1123.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: